Fisher Danina

SEC Form 4 insider trading activity

Fisher Danina has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Oct 2, 2026.

On the most recent filing, Fisher Danina is listed as Director at Hepion Pharmaceuticals, Inc. Inside the rolling window, Fisher Danina reported 1 open-market purchase totaling $10K in HEPA and no open-market sales.

Companies traded

Other insiders at HEPA

Insider Buying

$10K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
HEPAPurchase$10KOct 2SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Fisher Danina made?

Fisher Danina has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does Fisher Danina trade?

Fisher Danina has filed SEC Form 4 disclosures for 1 company, including HEPA.

When was Fisher Danina's most recent SEC Form 4 filing?

Fisher Danina's most recent SEC Form 4 filing on Tracefour is dated Oct 2, 2026.

What is Fisher Danina's total buy and sell value in the current window?

Inside the rolling retention window, Fisher Danina bought $10K and sold $0 based on SEC Form 4 filings.

What was Fisher Danina's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 200,000 HEPA shares on 2026-09-29, worth $10K, per SEC Form 4 filings.